John B. Bode
John B. Bode's purchase track record
How the stock did after each of John B. Bode's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2025 | ZVRA | $46K | +7.7% | -4.6% | +6.7% |
| 3/19/2025 | ZVRA | $80K | +14.1% | -7.8% | +16.3% |
| 7/12/2024 | ZVRA | $59K | +39.5% | +38.6% | +3.8% |
| 9/5/2023 | ZVRA | $51K | +0.6% | +17.5% | +12.9% |
| 5/18/2023 | ZVRA | $50K | -2.2% | -15.3% | +7.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
NWTG noted among consumer discretionary stocks moving pre‑market. Newton Golf Company (NWTG) was listed among twelve consumer discretionary stocks that showed price movement in Monday’s pre‑market session, according to Benzinga. The pre‑market activity aligns with the stock’s high‑beta and recent volume spike, indicating heightened trading interest. The move occurs while the stock trades near the lower end of its 52‑week range.
Transaction History
| ZVRA | ▲ Buy | Option Exercise | 39,200 | $195K | 3/24/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 39,200 | $192K | 3/24/2026 | View on chart |
| NWTG | ▲ Buy | Grant | 18,549 | $0 | 1/30/2026 | View on chart |
| ZVRA | ▲ Buy | Open Market | 5,000 | $46K | 8/19/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 10,000 | $80K | 3/19/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 10,000 | $59K | 7/12/2024 | View on chart |
| ZVRA | ▲ Buy | Open Market | 10,000 | $51K | 9/5/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,390 | $7K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 300 | $2K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,000 | $5K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 4,759 | $24K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 100 | $505 | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,451 | $12K | 5/18/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.